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Abstract Interleukin-1 is a cytokine involved in the acute phase 
response against infection and injury. We obtained crystals of a 
complex of soluble, recombinant human interleukin-1 receptor 
and recombinant human interleukin-1 receptor antagonist, a nat- 
urally occurring antagonist. ° The crystals are suitable for X-ray 
analysis and diffract to 2.7 A resolution. Solvent content calcula- 
tions indicate that the crystals contain one receptor and one 
antagonist molecule per asymmetric unit. Other receptor to an- 
tagonist ratios are highly unlikely. These results suggest hat the 
interleukin-1 antagonist binds a single receptor molecule and does 
not cause receptor aggregation. 
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1. Introduction 
Interleukin-1 (IL-1) is a cytokine involved in the early phase 
of inflammation, the acute-phase r sponse. Interleukin-1 is pro- 
duced by activated macrophages, T-cells, and other cell types 
and triggers a wide variety of inflammatory reactions [1]. The 
inflammatory response protects the organism against patho- 
gens, but interleukin-1 has also been implicated in a number of 
immune-related disorders uch as arthritis, inflammatory bowel 
disease and septic shock [2]. Molecules which are able to inhibit 
the interleukin-1 response could potentially be used as drugs to 
treat these disorders. 
Three naturally occurring IL-1 receptor ligands are known: 
two agonists, IL-lc~ and IL-lfl, and one antagonist, the IL-1 
receptor antagonist (IL-lra). These three ligands are proteins 
of about 150 amino acids with a molecular mass o f -  17.5 kDa. 
Crystal structures are available for all three ligands [3-8]. Two 
types of IL-1 receptors are known. The type I receptor is a 
glycoprotein of 552 amino acids with a molecular mass o f~80 
kDa [9]. The type II receptor has 385 amino acids and a mass 
of~60 kDa [10]. The IL-1 receptors consist of a ligand binding 
portion of~316 amino acids (type I) or ~310 amino acids (type 
II), comprised of three immunoglobulin-like domains, a trans- 
membrane region and an intra-cellular domain. Whereas the 
intra-cellular domain of the type I receptor is large (-215 amino 
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acids), the cytoplasmic domain of the type II receptor is small 
(only 29 amino acids). The extra-cellular domains of both re- 
ceptor types are distantly related and share ~28% identity. The 
type I receptor has been linked to a biological response [11], but 
not the type II receptor. It has been proposed that the type II 
receptor functions as a decoy target, binding excess interleukin- 
1 [12]. 
Here we report the crystallization of a complex of the extra- 
cellular, ligand-binding portion of the type I IL-1 receptor, 
consisting of three immunoglobulin-like domains, and IL-lra. 
2. Experimental 
Both the IL-1 receptor and the IL-lra used are recombinant proteins. 
The IL-lra was expressed in E. coli and purified as has been described 
before [8]. The soluble IL-1 receptor was cloned and expressed as 
follows. 
The full-length and extra-cellular domains, as determined from hy- 
drophobicity studies based on the sequence of the type I IL-1 receptor 
[13], were cloned by PCR from HepG2 Cell total RNA. PCR primers 
contained homology to the type I IL-1 receptor gene plus additional 
sequences to create restriction sites for cloning. The resulting PCR 
products were cloned into the vector pSRAlphaNeo [14]. 
The extra-cellular domain of the IL-1 type I receptor was edited by 
5 cycles of PCR with the oligonucleotides ON-72 (5'-TAGGCGGCC- 
GCCATGAAAGTGTTACTCAGACTTATTTGTTTCATAG-3') 
and ON-403 (5'-CGGAGAATTACTTCTGGAAATTAGTGACTG- 
G-Y). The amplified DNA was then digested with NotI and EcoRI and 
cloned into the baculovirus expression vector pVL1392 (Invitrogen). 
This plasmid was then digested with BgllI and XhoI, the BgllI site was 
filled in with Klenow and the receptor containing fragment was then 
ligated to the NheI (filled in) and XhoI digested fragment containing 
fl-galactosidase of the BlueBac vector (Invitrogen). The resulting plas- 
mid, BlueBac/IL-1R Exo, was then used to create arecombinant bacu- 
lovirus and scaled up through standard procedures (Invitrogen) to 
express the secreted IL-1 type I receptor extra-cellular domain. 
The soluble type I IL-1 receptor was expressed in baculovirus in- 
fected insect cells and purified from cell supernatants in a single step 
by affinity chromatography using MBP-IL-lra sepharose. The resin 
was washed extensively with PBS and the receptor was eluted with 0.1 
M glycine, 0.15 M NaC1 pH 3.0 and neutralized with 1 M Tris base. 
Receptor fractions were concentrated toapproximately 1 mg/ml using 
an Amicon stirred cell with a 10,000 kDa cut-off membrane. The puri- 
fied receptor was then dialyzed 2 times, 4 h each against 2 liters of 50 
mM (NH4)2CO3. After dialysis the receptor was quickly frozen in dry- 
ice/methanol and lyophilized overnight. 
The complex of the IL-1 receptor with the antagonist was prepared 
by mixing a solution of IL-1 receptor in 50 mM Tris (pH 7.5) and 150 
mM NaC1, with a solution of IL-lra in the same buffer. The receptor 
to antagonist ratio was 1:1. To get rid of aggregated material, the 
complex was passed through a membrane with a cut-off of 300 kDa 
using a filtron macrosep micro-concentrator and the complex was sub- 
sequently concentrated to a total protein concentration of about 18 
mg/ml using a centricon micro concentrator with a cut-off of 3 kDa. 
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The complex was crystallized at23°C using the hanging drop method. 
The drops were prepared by mixing 4/21 of the protein solution with 
1 /21 of reservoir solution containing 30% (w/v) PEG 3350, 400 mM 
MgCIz in 100 mM MOPS buffer (pH 7.0) and the drop was set to 
equilibrate against 1ml of reservoir solution. Crystals with dimensions 
up to 0.2 x 0.3 x 0.5 mm 3 grew between 2 weeks and 2 months. The 
crystals were analyzed with a Siemens area detector, mounted on a 
Siemens rotating anode generator using XDS software [15]. 
3. Results 
Analysis of the diffraction pattern showed that the space 
group was P212121, with a -- 47.2A, b = 84.6A and c -- 140.2A. 
SDS-PAGE of dissolved crystals howed that the crystals con- 
tain both the IL-1 receptor and the antagonist. Assuming one 
receptor molecule and one antagonist molecule per asymmetric 
unit, we obtain a V m of 2.22/~3/Da nd a solvent content of 
44.6% [16], which is in the middle of the range observed for 
protein crystals. Assuming two receptor molecules and one 
antagonist molecule, we would obtain a Vm of 1.28 A3/Da, 
corresponding to 3.9% solvent, which is extremely unlikely. We 
therefore conclude that the asymmetric unit of our crystals 
contains one receptor and one antagonist molecule. We col- 
lected a native data set to 2.7 A resolution, which contains 
15,631 unique reflections, based on 73,407 observations. The 
Rsym (on I ) is  6.0%. The 15,631 unique reflections represent 
97.2% of all possible reflections to 2.7 /~ resolution. We are 
currently in the process of solving the structure by using a 
combination ofheavy atom derivatives and molecular replace- 
ment. 
4. Discussion 
Our observation ofa 1 : 1 interleukin-1 receptor-ligand com- 
plex is fully consistent with recent results of Greenfeder et al. 
who report he presence of a second subunit of the interleukin-1 
receptor complex [17]. They named this protein the interleukin- 
1 receptor accessory protein. The authors propose on the basis 
of biochemical experiments that binding of agonists, but not of 
antagonists, brings together the interleukin-1 receptor and the 
accessory protein which could then lead to receptor activation. 
Our crystals are grown at physiological pH and the ionic 
strength of the crystallization solution is not extremely high. 
Under similar conditions, receptor aggregation was observed 
in crystals of receptor-ligand complexes of the human growth 
hormone receptor [18] and the tumor necrosis factor receptor 
[19]. If the IL-lra molecule would cause aggregation of IL-1 
receptor molecules, we would expect o see this aggregation i
the crystals. We therefore conclude that the IL-1 receptor forms 
1 : 1 complexes with its natural antagonist. Failure of the IL- 1 
receptor/IL-lra complex to bind the accessory protein [17] 
would provide a mechanism by which the antagonist blocks the 
receptor action. 
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